Moreover, according to the C1-C6 immune subtypes previously identified by investigators [10], we classified tumor samples by representative immune signatures and examined the RNA-seq level of PPARA, PPARD, PPARG, PPARGC1A, and PPARGC1B from C1 to C6, which were all seen to have differential expressions. This evidence concerns the gene PPARGC1A and neoplasm.